Gamida Cell

5 stories about Gamida Cell
ג'וליאן אדמס מנכ"ל גמידה

Gamida Cell announces $75 million financing with Highbridge Capital Management

The Israeli company is developing and commercializing cures for blood cancers and serious hematologic diseases

Gamida Cell Downprices Shares to Raise $50 Million Nasdaq IPO

28.10.18|Lilach Baumer
The Israel-based biotech company offered its shares at $8, below its previous intention of $13 to $15 per share
נאסד"ק וול סטריט

Novartis-Backed Gamida Downgrades Nasdaq IPO Expectations to $50-$60 Million

18.10.18|Lilach Baumer
The Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms
נאסד"ק וול סטריט

Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO

30.09.18|Dror Reich
The Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution
המדען הראשי ב כלל ביוטכנולוגיה ד"ר ג'וליאן אדמס

Pharma Veteran Julian Adams takes Helm at Gamida Cell

21.11.17|Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor